Outcomes of CAG regimen for refractory biphenotypic acute leukemia patients.
- Author:
Guang-Sheng HE
1
;
Xiang ZHANG
;
De-Pei WU
;
Ai-Ning SUN
;
Zheng-Ming JIN
;
Hui-Ying QIU
;
Miao MIAO
;
Xiao-Wen TANG
;
Zheng-Zheng FU
;
Yue HAN
Author Information
- Publication Type:Journal Article
- MeSH: Aclarubicin; administration & dosage; adverse effects; Adult; Antineoplastic Combined Chemotherapy Protocols; administration & dosage; adverse effects; Cytarabine; administration & dosage; adverse effects; Female; Granulocyte Colony-Stimulating Factor; administration & dosage; adverse effects; Humans; Leukemia, Biphenotypic, Acute; drug therapy; Male; Remission Induction; Treatment Outcome; Young Adult
- From: Chinese Medical Sciences Journal 2009;24(3):178-181
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo evaluated the efficiency of low-dose cytosine arabinoside plus aclarubicin with concurrent administration of granulocyte colony-stimulating factor (CAG) regimen for refractory biphenotypic acute leukemia (BAL).
METHODSWe treated 5 refractory BAL patients by CAG regimen (10 mg x m(-2) cytosine arabinoside subcutaneously administrated every 12 hours, day 1-14; 5-7 mg x m(-2) aclarubicin intravenously administrated daily, day 1-8; and concurrently used 200 microg x m(-2) x d(-1) granulocyte colony-stimulating factor subcutaneously) from November 2002 to April 2007. The efficacy of the regimen was evaluated by response rate, and the side effects were also measured.
RESULTSThe complete remission rate was 80%, median duration of absolute neutrophil count < 5.0 x 10(8)/L and platelet count < 2.0 x 10(10)/L was day 13 and day 1, respectively; and the infection rate was low (III-IV infection rate, 20.00%).
CONCLUSIONCAG regimen as remission induction chemotherapy for BAL patients is effective with a high remission rate and low toxicity.
